You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 9,949,994


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,949,994 protect, and when does it expire?

Patent 9,949,994 protects VEKLURY and is included in one NDA.

Protection for VEKLURY has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and twenty-seven patent family members in forty-four countries.

Summary for Patent: 9,949,994
Patent landscape, scope, and claims:
Title:Methods for treating Filoviridae virus infections
Abstract: Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV: ##STR00001## The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.
Inventor(s): Chun; Byoung Kwon (Pleasanton, CA), Clarke; Michael O'Neil Hanrahan (Redwood City, CA), Doerffler; Edward (Foster City, CA), Hui; Hon Chung (Foster City, CA), Jordan; Robert (Foster City, CA), Mackman; Richard L. (Millbrae, CA), Parrish; Jay P. (El Dorado Hills, CA), Ray; Adrian S. (Burlingame, CA), Siegel; Dustin (San Carlos, CA)
Assignee: GILEAD SCIENCES, INC. (Foster City, CA)
Application Number:15/246,240
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 9,949,994

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead Sciences Inc VEKLURY remdesivir POWDER;INTRAVENOUS 214787-001 Oct 22, 2020 RX Yes Yes 9,949,994*PED ⤷  Subscribe Y ⤷  Subscribe
Gilead Sciences Inc VEKLURY remdesivir SOLUTION;INTRAVENOUS 214787-002 Oct 22, 2020 RX Yes Yes 9,949,994*PED ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.